EMA Passes GSK’s Mekinist, Extends Indications For Gilenya And Pradaxa
This article was originally published in The Pink Sheet Daily
Executive Summary
The EMA recommended authorizing a single drug this month, GSK’s Mekinist, while giving the nod to seven others, including Novartis’ Gilenya and Boehringer Ingelheim’s Pradaxa.